Treat-to-target of rheumatoid arthritis and potential determinants

HUANG Ling-ling; XU Jian-hua; XU Sheng-qian; XIAO Hui; CHANG Ling; LIU Na; MA Qin

doi:10.16462/j.cnki.zhjbkz.2016.06.012

Volume 20 Issue 6

Jun. 2016

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2016 > 20(6): 586-589

HUANG Ling-ling, XU Jian-hua, XU Sheng-qian, XIAO Hui, CHANG Ling, LIU Na, MA Qin. Treat-to-target of rheumatoid arthritis and potential determinants[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 586-589. doi: 10.16462/j.cnki.zhjbkz.2016.06.012

Citation:

HUANG Ling-ling, XU Jian-hua, XU Sheng-qian, XIAO Hui, CHANG Ling, LIU Na, MA Qin. Treat-to-target of rheumatoid arthritis and potential determinants[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 586-589. doi: 10.16462/j.cnki.zhjbkz.2016.06.012

Citation:

PDF( 913 KB)

Treat-to-target of rheumatoid arthritis and potential determinants

doi: 10.16462/j.cnki.zhjbkz.2016.06.012

Department of rheumatology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Received Date: 2015-12-04
Rev Recd Date: 2016-03-18

Abstract

Abstract

Objective To investigate treat-to-target rate of rheumatoid arthritis (RA), analyse its potential determinants and to improve treat-to-target rate of RA. Methods 300 RA patients were recruited and clinical data were recorded detailedly. All 300 RA patients were devided into treat-to-target and not treat-to-target according to the disease activity score in 28 joints (DAS28). Results The treat-to-target rates of this study were 36.7%;RA patients who were treated-to-target had younger age, higher education, fewer swollen joint counts,fewer tender joint counts, lower visual analogue scale, lower patient global assessment, lower physician global assessment (PGA), lower rheumatoid factor, lower erythrocyte sedimentation rate, lower C-reactive protein level, lower joint function classification, lower health assessment questionnaire score and more regular treatment with disease-modifying anti-rheumatic drugs (≥3 months) when compared with those were not. Logistic regression analysis revealed that low PGA, low joint function classification and low C-reactive protein were independent determinants of treat-to-target. Conclusions The treat-to-target rate of RA patients was still low. Regular treatment with DMARDs was important to treat-to-target in RA. Low PGA, low C-reactive protein and low joint function classification were significant independent determinants for RA treat-to-target.
- Arthritis,rheumatoid,
- Logistic models,
- Risk factors

FullText(HTML)

References(15)

References

Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update [J]. Ann Rheum Dis, 2014,73:492-509.

Sokka T, Hetland ML, Mäkinen H, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries [J]. Arthritis Rheum, 2008,58(9):2642-2651.

Lutf A, Poil AR, Hammoudeh M. Characteristics of patients With rheumatoid arthritis in Qatar:a cross-sectional study [J]. Int J Rheum Dis, 2014,17(1):63-65.

Wang GY, Zhang SL, Wang XR, et al. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey [J]. Clin Rheumatol, 2015,34(2):221-230.

邓雪蓉,周炜,王昱,等. 类风湿关节炎在不同治疗方案下的达标情况及影响因素分析 [J]. 中华风湿病学杂志, 2014,18(6):365-368.

Katchamart W, Johnson S, Lin HJ, et al. Predictors for remission in rheumatoid Arthritis patients:a systematic review [J]. Arthritis Care Res(Hoboken), 2010,62(8):1128-1143.

Ellerby N, Mattey DL, Packham J, et al. Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis [J]. Ann Rheum Dis, 2014,73(11):e74.

Choy T, Bykerk VP, Boire G, et al. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort [J]. Rheumatology (Oxford), 2014,53(3):482-490.

Cannon GW, Wang BC, Park GS, et al. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial Experience [J]. Clin Exp Rheumatol, 2013,31(6):919-925.

van den Broek M, Dirven L, Klarenbeek NB, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study [J]. Ann Rheum Dis, 2012,71(2):245-248.

Ma MH, Scott IC, Dahanayake C, et al. Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen [J]. J Rheumatol, 2014,41(7):1298-1303.

Emery P, Hammoudeh M, Fitzgerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis [J]. N Engl J Med, 2014,371(19):1781-1792.

Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period [J]. Ann Rheum Dis, 2015,74(1):19-26.

Nakashima Y, Kondo M, Fukuda T, et al. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data [J]. Mod Rheumatol, 2014,24(2):258-264.

Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study [J]. Ann Rheum Dis, 2004,63(6):675-680.

Relative Articles

Supplements(0)

Cited By

Proportional views